Cargando…

Valsartan ameliorates ageing-induced aorta degeneration via angiotensin II type 1 receptor-mediated ERK activity

Angiotensin II (Ang II) plays important roles in ageing-related disorders through its type 1 receptor (AT(1)R). However, the role and underlying mechanisms of AT1R in ageing-related vascular degeneration are not well understood. In this study, 40 ageing rats were randomly divided into two groups: ag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shan, HaiYan, Zhang, Siyang, Li, Xuelian, yu, Kai, Zhao, Xin, Chen, Xinyue, Jin, Bo, Bai, XiaoJuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508146/ https://www.ncbi.nlm.nih.gov/pubmed/24548645 http://dx.doi.org/10.1111/jcmm.12251

Ejemplares similares

Proinflammatory Role of Angiotensin II in the Aorta of Normotensive Mice
por: de Lima, Rariane Silva, et al.
Publicado: (2019)

The angiotensin II type 1 receptor blocker valsartan in the battle against COVID‐19
por: de Ligt, Marlies, et al.
Publicado: (2021)

Sex Differences in the Effectiveness of Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Sacubitril–Valsartan for the Treatment of Heart Failure
por: Sohani, Zahra N., et al.
Publicado: (2023)

Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
por: Dargad, Ramesh R., et al.
Publicado: (2018)

Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach
por: Nixon, R M, et al.
Publicado: (2009)

Angiotensin II Receptor–Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats
por: Seki, Takunori, et al.
Publicado: (2017)

Blood pressure‐independent inhibition of Marfan aortic root widening by the angiotensin II receptor blocker valsartan
por: Tehrani, Arash Y., et al.
Publicado: (2021)

Testosterone downregulates angiotensin II type-2 receptor via androgen receptor-mediated ERK1/2 MAP kinase pathway in rat aorta
por: Mishra, Jay S, et al.
Publicado: (2016)

Effect of Angiotensin II on Chondrocyte Degeneration and Protection via Differential Usage of Angiotensin II Receptors
por: Nishida, Takashi, et al.
Publicado: (2021)

Angiotensin II receptor Neprilysin inhibitor (LCZ696) compared to Valsartan attenuates Hepatotoxicity in STZ-induced hyperglycemic rats
por: Alqahtani, Faleh, et al.
Publicado: (2020)

Role of lipoxygenase products in the effects of angiotensin II in the isolated aorta and perfused heart of the rat
por: Dam, J. P. M., et al.
Publicado: (1995)

Disparate biomechanical properties of the aorta in non‐aneurysmal and aneurysmal mice treated with angiotensin II
por: De Moudt, Sofie, et al.
Publicado: (2022)

In silico study of inhibitory capacity of sacubitril/valsartan toward neprilysin and angiotensin receptor
por: Jovanović, Jelena Đorović, et al.
Publicado: (2022)

AngiotensinII Preconditioning Promotes Angiogenesis In Vitro via ERKs Phosphorylation
por: Guan, Aili, et al.
Publicado: (2012)

Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect
por: Tashiro, Kohei, et al.
Publicado: (2020)

Rutaecarpine Ameliorates Pressure Overload Cardiac Hypertrophy by Suppression of Calcineurin and Angiotensin II
por: Li, Shujun, et al.
Publicado: (2021)

Neprilysin Inhibitor–Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E- Deficient Mice
por: Zhang, Hui, et al.
Publicado: (2019)

Angiotensin-(1-9) ameliorates pulmonary arterial hypertension via angiotensin type II receptor
por: Cha, Seung Ah, et al.
Publicado: (2018)

The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat
por: Habibi, Javad, et al.
Publicado: (2019)

Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker
por: Tan, Nicholas Y., et al.
Publicado: (2021)

Angiotensin II-Induced Vasoconstriction via Rho Kinase Activation in Pressure-Overloaded Rat Thoracic Aortas
por: Terada, Yuka, et al.
Publicado: (2021)

The impact of a dose of the angiotensin receptor blocker valsartan on post‐myocardial infarction ventricular remodelling
por: Park, Kyungil, et al.
Publicado: (2018)

Sacubitril/valsartan versus angiotensin inhibitors and arrhythmia endpoints in heart failure with reduced ejection fraction
por: Fernandes, Amanda D.F., et al.
Publicado: (2021)

Time to switch angiotensin-converting enzyme inhibitors/angiotensin receptor blockers to sacubitril/valsartan in patients with cancer therapy-related cardiac dysfunction
por: Xi, Qianlan, et al.
Publicado: (2022)

Curcumin Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysm by Inhibition of Inflammatory Response and ERK Signaling Pathways
por: Hao, QingQing, et al.
Publicado: (2014)

Increased contractile responses to 5-hydroxytryptamine and Angiotensin II in high fat diet fed rat thoracic aorta
por: Ghatta, Srinivas, et al.
Publicado: (2004)

Contractile Force Is Enhanced in Aortas from Pendrin Null Mice Due to Stimulation of Angiotensin II-Dependent Signaling
por: Sutliff, Roy L., et al.
Publicado: (2014)

Effect of Statins, Metformin, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers on Age-Related Macular Degeneration
por: Lee, Hyesung, et al.
Publicado: (2019)

LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
por: Lefkowitz, Martin P
Publicado: (2015)

Effect of the angiotensin receptor–neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide
por: Ayalasomayajula, Surya, et al.
Publicado: (2018)

Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real‐world study in Taiwan
por: Chang, Po‐Cheng, et al.
Publicado: (2020)

Effect of angiotensin II type 1 receptor antagonist valsartan on cardiac remodeling and left ventricular function in patients with acute ST-elevation myocardial infarction.
por: Eduard, Ovricenco, et al.
Publicado: (2008)

Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload
por: Nordén, Einar Sjaastad, et al.
Publicado: (2021)

Angiotensin II and the ERK pathway mediate the induction of myocardin by hypoxia in cultured rat neonatal cardiomyocytes
por: Chiu, Chiung-Zuan, et al.
Publicado: (2010)

Sodium Ferulate Protects against Angiotensin II-Induced Cardiac Hypertrophy in Mice by Regulating the MAPK/ERK and JNK Pathways
por: Hu, Bo, et al.
Publicado: (2017)

Mechanisms of potentiation of Angiotensin II-induced contractile response of isolated rat aorta by hydrogen peroxide and tert-butyryl hydroperoxide
por: Patel, R. J., et al.
Publicado: (2009)

Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors
por: Norberg, Helena, et al.
Publicado: (2019)

Dual Angiotensin Receptor-Neprilysin Inhibition With Sacubitril/Valsartan Attenuates Systolic Dysfunction in Experimental Doxorubicin-Induced Cardiotoxicity
por: Boutagy, Nabil E., et al.
Publicado: (2020)

Angiotensin II Signaling in Human Preadipose Cells: Participation of ERK(1,2)-Dependent Modulation of Akt
por: Dünner, Natalia, et al.
Publicado: (2013)

Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin‐Converting Enzyme Inhibitor or Angiotensin‐Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure
por: Albert, Nancy M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_agaonii03oqi2b0j15md00ijum